All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke with Giovanna Lucchini, Great Ormond Street Hospital, London, UK. We asked, How does graft-versus-host disease (GvHD) affect outcomes for pediatric patients undergoing allogeneic stem cell transplantation (allo-SCT) for acute lymphoblastic leukemia (ALL)?
How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?
Lucchini begins by describing how background disorders impact GvHD in patients post transplant. Lucchini then discusses the concept of engineering GvHD that is 'enough, but not too much' and highlights the need for more strategies to support patients and control GvHD.
When should we consider allo-HSCT in a patient with ALL? And when not?
During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel, Maria Sklodowska-Curie National Research...
The correlation between CD34+ cell dose and DFS in matched-related donor PBSC allo-SCT
To evaluate the impact of infused CD34+ cell doses on PBSC allo-SCT matched-related donor outcomes, Yasuhisa Yokoyama, University of Tsukuba, Tsukuba, JP, and...
Subscribe to get the best content related to ALL delivered to your inbox